S-Adenosylhomocysteine

S-Adenosylhomocysteine

SCHEMBL10871157

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CSCCC(N)C(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 9/20 1.00
DNMT1 P26358 7/20 1.00
DNMT3B Q9UBC3 6/20 1.00
EZH2 Q15910 4/20 1.00
CARM1 Q86X55 2/20 1.00
EHMT2 Q96KQ7 2/20 1.00
PRMT1 Q99873 2/20 1.00
NNMT P40261 2/20 1.00
TRDMT1 O14717 1/20 1.00
PRMT5 O14744 1/20 1.00
SUV39H1 O43463 1/20 1.00
PRMT3 O60678 1/20 1.00
INMT O95050 1/20 1.00
NSD2 O96028 1/20 1.00
PNMT P11086 1/20 1.00
HNMT P50135 1/20 1.00
WDR5 P61964 1/20 1.00
KMT2A Q03164 1/20 1.00
SETDB1 Q15047 1/20 1.00
RBBP5 Q15291 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
S-Adenosylhomocysteine SCHEMBL804238 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL13033864 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL17087726 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL14434697 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL18826562 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL17316165 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL13073142 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL12378912 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL21160481 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL14411397 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540946-B2 Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample COMPLETE OMICS INC. (US) 2026-02-03 US disclosed
US-12329726-B2 Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-06-17 US disclosed
US-20240053355-A1 METHODS AND SYSTEMS FOR DETECTING AND QUANTIFYING LARGE NUMBER OF MOLECULE BIOMARKERS FROM A BODY FLUID SAMPLE COMPLETE OMICS INTERNATIONAL INC. 2024-02-15 US disclosed
US-20230285322-A1 Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-09-14 US disclosed
US-11622948-B2 Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-04-11 US disclosed
US-11427858-B2 Methods of detecting modified and unmodified DNA TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2022-08-30 US disclosed
EP-4031681-A1 LABELLING OF BIOMOLECULES The University of Birmingham (GB) 2022-07-27 EP disclosed
CN-114712510-A Application of small molecule inhibitor in preparation of medicine for treating and intervening related diseases through METTL3 中国人民解放军空军军医大学 2022-07-08 CN disclosed
WO-2021053347-A1 LABELLING OF BIOMOLECULES THE UNIVERSITY OF BIRMINGHAM (GB) 2021-03-25 WO disclosed
WO-2020225946-A1 METHOD FOR EVALUATING SAMPLE, ANALYSIS METHOD, METHOD FOR DETECTING DEGRADED SAMPLE, MARKER FOR DETECTING DEGRADED BLOOD PLASMA SAMPLE, AND MARKER FOR DETECTING DEGRADED SERUM SAMPLE 株式会社島津製作所 2020-11-12 WO disclosed
US-20200340032-A1 METHODS OF DETECTING MODIFIED AND UNMODIFIED DNA TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2020-10-29 US disclosed
US-20200261379-A1 BIOMARKERS FOR EFFICACY OF PROPHYLACTIC TREATMENTS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS BPG BIO, INC. 2020-08-20 US disclosed
EP-3662079-A1 METHODS OF DETECTING MODIFIED AND UNMODIFIED DNA Technion Research & Development Foundation Limited (IL) 2020-06-10 EP disclosed
WO-2019026075-A9 METHODS OF DETECTING MODIFIED AND UNMODIFIED DNA TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2019-08-29 WO disclosed
WO-2019026075-A1 METHODS OF DETECTING MODIFIED AND UNMODIFIED DNA TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2019-02-07 WO disclosed
CN-101928749-A Method for detecting S-adenosylmethionine (AdoMet)-dependent methyltransferase UNIV JINAN 2010-12-29 CN disclosed
US-4605625-A RACEMIZATION WITH PSEUDOMONAS NIPPON ZEON CO., LTD. (JP) 1986-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540946-B2 Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample MYADM, EPCAM, CD14 DOT1L 4173/4885DNMT1 2642/4885DNMT3B 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.